Reuters logo
BRIEF-Mesoblast provides data from mid-stage trial on cell therapy MPC-300-IV
February 15, 2017 / 11:27 PM / 9 months ago

BRIEF-Mesoblast provides data from mid-stage trial on cell therapy MPC-300-IV

Feb 15 (Reuters) - Mesoblast Ltd :

* Announced 39-week data from phase 2 trial in patients with rheumatoid arthritis resistant to anti-tumor necrosis factor agents

* Results also demonstrated durable improvement in clinical symptoms, physical function, disease activity relative to placebo

* Results showed single intravenous infusion of proprietary allogeneic cell therapy product candidate MPC-300-IV well tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below